Company · founded 2011
Modulation Therapeutics (United States)
Morgantown, United States · modulationtherapeutics.com
- Citations, last 5 years
- 61
- Works, last 5 years
- 11
- h-index
- 16
- Scientists listed
- 1
- Grants since 2016
- 18
Grants received
2023–2024 · research · R41
MTI-301 a SCD1 inhibitor for the treatment of NASH
Werner Geldenhuys · Modulation Therapeutics (United States) · funded by National Institutes of Health
2022–2025 · research · R44
Modulation of cancer induced immune suppression via inhibition of SCD1
John A. Copland · Modulation Therapeutics (United States) · funded by National Institutes of Health
2022–2025 · research · R44
Modulation of cancer induced immune suppression via inhibition of SCD1
John A. Copland · Modulation Therapeutics (United States) · funded by National Institutes of Health
2022–2023 · research · R44
Modulation of cancer induced immune suppression via inhibition of SCD1
John A. Copland · Modulation Therapeutics (United States) · funded by National Institutes of Health
2022–2026 · research · R44
Modulation of cancer induced immune suppression via inhibition of SCD1
John A. Copland · Modulation Therapeutics (United States) · funded by National Institutes of Health
2019–2021 · research · R41
Development of mitoNEET agonists for the treatment of stroke
Werner Geldenhuys · Modulation Therapeutics (United States) · funded by National Institutes of Health
2018–2023 · research · R43
Development of an a MC1R selective companion diagnostic imaging probe
Jose Gabriel Garcia · Modulation Therapeutics (United States) · funded by National Institutes of Health
2017–2023 · research · R44
Development of PEGylated MTI-101 for the treatment of relapsed Myeloma
Karen E Hayes · Modulation Therapeutics (United States) · funded by National Institutes of Health
2017–2018 · research · R44
Development of PEGylated MTI-101 for the treatment of relapsed Myeloma
Werner Geldenhuys · Modulation Therapeutics (United States) · funded by National Institutes of Health
2017–2019 · research · R41
Osteopontin-targeted therapy for primary CNS lymphoma
John A. Copland · Modulation Therapeutics (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Development of PEGylated MTI-101 for the treatment of relapsed Myeloma
Werner Geldenhuys · Modulation Therapeutics (United States) · funded by National Institutes of Health
2017–2021 · research · R44
Mechanism underpinning synergy with combined treatment of MTI-101 and Dexamethasone in Multiple Myeloma
Lori Hazlehurst · Modulation Therapeutics (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Development of PEGylated MTI-101 for the treatment of relapsed Myeloma
Werner Geldenhuys · Modulation Therapeutics (United States) · funded by National Institutes of Health
2017–2019 · contract · N44
"Targeted Ac-225-radiopharmaceutical for metastatic uveal melanoma"Period of Performance: 9/18/2017 - 9/17/2019
Rikki Waterhouse · Modulation Therapeutics (United States) · funded by National Institutes of Health
2017–2018 · research · R44
Development of PEGylated MTI-101 for the treatment of relapsed Myeloma
Werner Geldenhuys · Modulation Therapeutics (United States) · funded by National Institutes of Health
2016–2017 · research · R41
Novel SCD1 inhibitors for treatment of cancer
John A. Copland · Modulation Therapeutics (United States) · funded by National Institutes of Health
2016–2020 · research · R42
Novel SCD1 inhibitors for treatment of cancer
John A. Copland · Modulation Therapeutics (United States) · funded by National Institutes of Health
2016–2022 · research · R42
Novel SCD1 inhibitors for treatment of cancer
John A. Copland · Modulation Therapeutics (United States) · funded by National Institutes of Health
